key: cord-0955379-f09ybjmz
authors: Deya-Martinez, A.; García-García, A.; Gonzalez-Navarro, E.A.; Yiyi, L.; Vlagea, A.; Jordan, I.; Fumadó, V.; Fortuny, C.; Español, M.; Launes, C.; Esteve-Solé, A.; Juan, M.; Pascal, M.; Alsina, L.
title: COVID-19 in children and young adults with moderate/severe inborn errors of immunity in a high burden area in pre-vaccine era
date: 2021-08-12
journal: Clin Immunol
DOI: 10.1016/j.clim.2021.108821
sha: ba43d60689dd2a4aa9907a756db53eadb477b9c8
doc_id: 955379
cord_uid: f09ybjmz

BACKGROUND: Information regarding inborn error of immunity (IEI) as a risk factor for severe COVID-19 is scarce. We aimed to determine if paediatric patients with moderate/severe IEI got COVID-19 at the same level as the general population, and to describe COVID-19 expression. MATERIAL AND METHODS: We included patients with moderate/severe IEI aged 0–21 years old: cross-sectional study (June2020) to determine the prevalence of COVID-19; prospective study (January2020-January2021) including IEI patients with COVID-19. Assays used: nasopharyngeal swab SARS-CoV-2 PCR and SARS-CoV-2-specific immunoglobulins. RESULTS: Seven from sixty-five patients tested positive (prevalence: 10.7% (7%–13%)) after the first SARS-COV-2 wave and 13/15 patients diagnosed with COVID-19 had an asymptomatic/mild course. CONCLUSIONS: In our area, prevalence of COVID-19 in moderate/severe IEI paediatric patients after the first wave was slightly higher than in the general population. The majority of patients presented a benign course, suggesting a possible protective factor related with age despite IEI.

In children, a milder course of COVID-19 compared with adults has been reported worldwide 1 with a very low proportion of symptomatic paediatric patients progressing to acute respiratory distress syndrome or multiorgan system dysfunction 6, 7 .

The main factors related to critical cases are age (>65), male gender, and the presence of certain comorbidities such as diabetes, hypertension, chronic respiratory disease, cancer, and cardiovascular disease 8, 9 .

Although inborn errors of immunity (IEI) have been assumed to be a risk factor for COVID-19, there is as yet limited information, mainly from adults, and often contradictory at that, about the real impact of COVID-19 on them. Recent studies suggest that only certain IEIs may predispose to severe COVID-19, whereas others could represent a protective factor 10,11, 12, 13, 14, 15, 16 .

Nevertheless, reports on paediatric IEI patients are still scarce.

The objectives of the study were first to determine, through a prevalence study, whether children and young adults with moderate/severe IEI living in a high burden area of SARS-CoV-2 infection became infected at the same level as the general population in the first wave, and, second, to describe their clinical presentation of SARS-CoV-2 infection prior to the vaccination era.

The study was carried out in a tertiary centre dedicated exclusively to maternal 

Of the 76 patients selected with moderate/severe IEI from our cohort, 65 agreed to participate. The baseline characteristics of the cohort are detailed in Table 1 and Sixteen percent of the patients were exposed to confirmed/suspected COVID- 19 cohabiting relatives (not all tested for SARS-CoV-2, due to the limited testing during the first wave of the pandemic in Spain). A total of 7 IEI patients were confirmed as having been infected with SARS-COV-2 by means of SARS-CoV-J o u r n a l P r e -p r o o f 2 serologies (7/7) ( Table 1) , which represents a prevalence of 10.7% (7%-13%).

Prior to the vaccination era (that is, January 2020 -January 2021), a total of 15 IEI patients were confirmed as infected by SARS-CoV-2: 2/15 by positive PCR 

The present study was designed to analyse the prevalence of SARS- Thus, IEI was initially listed as one theoretical risk factor for symptomatic/severe COVID-19. Our cohort ( 

This is the first study focused on paediatric patients with IEI and the impact on COVID-19. Our data show a higher infection rate, but without clinical severity except in two patients with MyD88 deficiency, suggesting that other factors such as younger age, absence of comorbidity, and more highly 'trained' immunity due to greater exposure to viral respiratory infections in IEI patients might be more important determinants of COVID-19 outcome than the immune deficiency per se. In the event that these data are confirmed in larger paediatric IEI cohorts, these findings could have an impact on future SARS-CoV-2 infection prevention recommendations for this population.

We are indebted to the "Biobanc de l'Hospital Infantil Sant Joan de Déu per a la Investigació" integrated in the Spanish Biobank Network of ISCIII for sample and data procurement. Data are expressed as (median (min-max) and percentage) *immunosupressants used in the PID cohort: mofetil mycophenolate, rapamycin, azathioprine, abatacept. **respiratory infections: influenza-like syndrome with fever > 37ºC, cough without fever, otitis, pneumonia, bronchitis, and others. ***cutaneous lesions: urticaria, pityriasis, papular exanthema ****invasive infections: sepsis (3), bacterial pneumonia (2) 

Systematic review of COVID-19 in children show milder cases and a better prognosis than adults

Virology, epidemiology, pathogenesis and control of COVID-19

Profiling early humoral response to diagnose novel coronavirus disease (COVID-19)

SARS-CoV-2 in children: spectrum of disease, transmission and immunopathological underpinnings

COVID-19 in children in the United States: intensive care admissions, estimated total infected, and projected numbers of severe pediatric cases in 2020

Primary immunodeficiency diseases in COVID-19 pandemic: A predisposing or protecting factor?

Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover

COVID-19 in a child with primary specific antibody deficiency

Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City

Amsterdam UMC Covid-19 Biobank; COVID Human Genetic Effort

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19

COVID-19 and primary immunodeficiency: one-year experience

Quality standard for the enumeration of CD4+ lymphocytes in infants and children exposed to or infected with human immunodeficiency virus

Characteristics and outcomes of coronavirus infection in children: the role of viral factors and an immunocompromised state

Immunodeficiencies primaries, cal pensar-hi? Pediatria Catalana

COVID-19/INFORMES%20COVID-19%202021/Informe%20COVID-19.%20Nº%2076_28%20de%20abril%20de

Kids Corona Project. The spectrum of COVID-19 disease in adolescents

Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel

COVID-19 in patients with primary and secondary immunodeficiency: The United Kingdom experience

Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency

Experimental and natural infections in MyD88-and IRAK-4-deficient mice and humans

Varying illness severity in patients with MyD88 deficiency infected with coronavirus SARS-CoV-2

Similarities and differences between the immunopathogenesis of COVID-19-related pediatric multisystem inflammatory syndrome and Kawasaki disease

Will children reveal their secret? The coronavirus dilema

IgA-Ab response to spike glycoprotein of SARS-CoV-2 in patients with COVID-19: A longitudinal study

IgA dominates the early neutralizing antibody response to SARS-CoV-2

Baseline characteristics of the IEI cohort included in the study # Data are expressed as (median (min-max) and percentage) *immunosupressants used in the PID cohort: mofetil mycophenolate, rapamycin, azathioprine, abatacept. **respiratory infections: influenza-like syndrome with fever > 37ºC, cough without fever, otitis, pneumonia, bronchitis, and others. ***cutaneous lesions: urticaria, pityriasis, papular exanthema ****invasive infections: sepsis (3), bacterial pneumonia (2), osteoarthicular infection